Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype: Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/FTD.0b013e318260b46ePMID 22777153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

  2011cited by this paper
• Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

  2011cited by this paper
• Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

  2011cited by this paper
• Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

  2011influential reference
• Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

  2011influential reference
• Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

  2010influential reference
• Desenvolvimento de metodologia para a determinação dos genótipos principais dos genes CYP2D6, CYP2C19 e CYP2C9: aplicação na farmacogenética

  2010cited by this paper
• The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

  2010cited by this paper
• CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug? 1

  2009cited by this paper
• CYP2D6 and tamoxifen: DNA matters in breast cancer

  2009cited by this paper
• Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

  2009cited by this paper
• Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

  2009cited by this paper
• Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

  2009influential reference
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? / CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?

  2009influential reference
• Pharmacogenomics of tamoxifen therapy.

  2009cited by this paper
• The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

  2008cited by this paper
• Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

  2008cited by this paper
• Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics

  2008cited by this paper
• Reversed phase HPLC determination of tamoxifen in dog plasma and its pharmaco-kinetics after a single oral dose administration

  2008cited by this paper
• Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients

  2008cited by this paper
• CYP2D6 polymorphisms and the impact on tamoxifen therapy.

  2007influential reference
• Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

  2007cited by this paper
• Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

  2007cited by this paper
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006influential reference
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005influential reference
• Dextromethorphan metabolic phenotyping in an Iranian population

  2005cited by this paper
• Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer

  2005cited by this paper
• Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

  2004cited by this paper
• Systematic toxicological analysis by high-performance liquid chromatography with diode array detection (HPLC-DAD)

  2004influential reference
• A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects

  2004cited by this paper
• Aging May Be Associated with Concentrations of Tamoxifen and Its Metabolites in Breast Cancer Patients

  2003cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper
• Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.

  2003cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

  2002cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex (TM) and Tamoxifen Alone or in Combination' (ATAC) trial

  2001cited by this paper
• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.

  2001cited by this paper
• Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial

  2001cited by this paper
• Ongoing research to identify environmental risk factors in breast carcinoma

  2000cited by this paper
• The CYP2D Subfamily

  1996cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper

• Pharmacogenetic Testing in Admixed Populations: Frequency of the AMR PGx Working Group Tier 1 Variant Alleles in Brazilians.

  2025cites this paper
• From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment

  2025cites this paper
• Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

  2022cites this paper
• Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis

  2021cites this paper
• Resolving discordant CYP2D6 genotyping results in Thai: platform limitations and novel haplotypes.

  2021cites this paper
• CYP2D6 Allele Frequency in Five Malaria Vivax Endemic Areas From Brazilian Amazon Region

  2021influential citation
• Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer

  2021cites this paper
• Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health

  2021cites this paper
• Pharmacogenomics research and clinical implementation in Brazil

  2019cites this paper
• The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer

  2019cites this paper
• A novel and simple LC-MS/MS quantitative method for dextromethorphan and dextrorphan in oral fluid.

  2019cites this paper
• Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen

  2019cites this paper
• Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

  2018cites this paper
• Pharmacogenetic testing in oncology: a Brazilian perspective

  2018cites this paper
• Tamoxifentherapie-begleitende CYP 2 D 6-Testung : Outline zum aktuellen wissenschaftlichen

  2018cites this paper
• Determination of CYP 2 D 6 * 3 and * 4 allele frequency among Turkish population Türk popülasyonunda CYP 2 D 6 * 3 ve * 4 allel frekansının saptanması

  2018cites this paper
• Endocrine Therapy in Older Women with Early-Stage Hormone Sensitive Breast Cancer

  2017cites this paper
• Tamoxifentherapie-begleitende CYP2D6-Testung: Outline zum aktuellen wissenschaftlichen Kenntnisstand // Tamoxifen-therapy and CYP2D6-Testing: The State of Knowledge

  2017cites this paper
• Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels

  2017cites this paper
• Are plasma concentrations of tamoxifen active metabolites sufficient to ensure therapeutic efficacy for tamoxifen treated women with breast cancer in Poland

  2016cites this paper
• Clinical feasibility of dried blood spots: Analytics, validation, and applications.

  2016cites this paper
• CYP450 genotype and pharmacogenetic association studies: a critical appraisal.

  2016cites this paper
• Addressing phenoconversion: the Achilles' heel of personalized medicine

  2015cites this paper
• CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.

  2015cites this paper
• CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?

  2015cites this paper
• Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  2015cites this paper
• Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.

  2015cites this paper
• Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation

  2015cites this paper
• A Current Review of Cytochrome P450 Interactions of Psychotropic Drugs

  2014cites this paper
• Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients.

  2014cites this paper
• Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry

  2014cites this paper
• Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment

  2014cites this paper
• Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population

  2014cites this paper
• Evaluation of CYP2D6 Polymorphic Types and Their Effect on Tamoxifen Efficacy Among Turkish Tamoxifen Users with Breast Cancer

  2014cites this paper
• Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival

  2014influential citation
• CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

  2013cites this paper
• Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.

  2013cites this paper